You are here: Industry Insights > Bamlanivimab

News List

Lilly to begin pragmatic study of bamlanivimab for COVID-19 in New Mexico pharmaceutical-business-review
December 23, 2020
Eli Lilly and Company announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico.
Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19 worldpharmanews
December 11, 2020
The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's neutralizing antibody bamlanivimab (LY-CoV555) 700 mg.
Lilly, UnitedHealth to Study Bamlanivimab in High-risk COVID-19 contractpharma
December 07, 2020
The study will identify and treat a large, diverse population of high-risk individuals for COVID-19 with bamlanivimab under real-world conditions.
US buys additional 650,000 doses of Lilly’s Covid-19 antibody for $812.5m pharmaceutical-technology
December 04, 2020
The US government has entered into a purchase agreement worth $812.5m to procure 650,000 additional doses of Eli Lilly and Company’s neutralising antibody bamlanivimab (LY-CoV555) 700mg.
Samsung Biologics signs Covid-19 therapy manufacturing deal with Lilly pharmaceutical-technology
November 18, 2020
South Korean pharma firm Samsung Biologics has entered a long-term agreement with Eli Lilly and Company to manufacture its investigational Covid-19 virus neutralising antibody, bamlanivimab.
FDA grants emergency use authorisation to COVID-19 antibody bamlanivimab europeanpharmaceuticalreview
November 13, 2020
The neutralising antibody therapy bamlanivimab (LY-CoV555) is authorised for emergency use in recently diagnosed patients who are at risk of developing severe COVID-19.
FDA grants EUA for Lilly’s monoclonal antibody for Covid-19 treatment pharmaceutical-technology
November 11, 2020
The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) for Eli Lilly and Company’s monoclonal antibody, bamlanivimab (LY-CoV555) 700mg, to treat patients recently diagnosed with Covid-19.
AbCellera antibody gets US FDA EUA as monotherapy for COVID-19 treatment expresspharma
November 11, 2020
AbCellera’s partner, Eli Lilly and Company, will supply the US government with 300,000 doses of bamlanivimab for allocation to high-risk patients.
US to begin distribution of Bamlanivimab, COVID-19 antibody from Eli Lilly expresspharma
November 11, 2020
Bamlanivimab allocations to states and territories will be based on their number of hospitalised COVID-19 patients and the number of overall cases, informed government officials.
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine worldpharmanews
November 06, 2020
The New England Journal of Medicine has published data from the monotherapy arms of BLAZE-1, a Phase 2 study assessing the efficacy and safety of Eli Lilly and Company's (NYSE: LLY) bamlanivimab (LY-CoV555) - a neutralizing antibody - in the COVID-19 ...

Previous page 1 2 3 4 Next page